Genelife Clinical Research Pvt. Ltd.

27/07/2026

"Clinically proven." "Dermatologically tested." "Microbiome-friendly." "Gynaecologically approved."
These are some of the most common claims in cosmetics and personal care. They are also some of the most poorly substantiated — because the bar required to make them defensibly has risen significantly in recent years, while many brands are still relying on ingredient safety data or in vitro tests that no longer satisfy regulatory expectations.
The EU Cosmetics Regulation requires documented claim substantiation in every product information file. Advertising standards bodies in India, the UK, and across the EU are reviewing cosmetic claims with increasing rigour. Major retail chains require clinical study reports as part of product listing qualification.
The brands that will own the best shelf positions in the next five years are the ones building rigorous clinical evidence now — not after a regulatory challenge forces them to.
We've written a detailed guide to what cosmeceutical clinical evidence actually requires — for skin safety, efficacy, microbiome claims, and intimate care — and why India has become one of the most strategically valuable locations to generate it.

Walk into any pharmacy, department store, or open any beauty brand's website, and the language is confident and specific. "Clinically proven to reduce wrinkles by 47% in 4 weeks.

22/07/2026

India's Phase II–IV clinical trial CRO sector is under serious pressure right now. Not because of quality failures. Not because of science. Because two administrative transitions arrived simultaneously and the implementation burden has fallen on organizations that were not built to absorb it.

The mandatory CRO registration requirement — introduced under the September 2024 NDCT amendment, compliance deadline April 1, 2025 — created a registration queue that CDSCO had to process on top of its normal workload. Smaller CROs waited months for registration confirmation while studies that should have started sat on hold. Revenue delayed. Staff underutilised. Some organizations genuinely at risk.

Layered on top of that: the Sugam portal transition. The new DDRS system won't be fully delivered until late 2027 at the earliest. In the interim, Phase II and III applications submitted in 2024 and 2025 are sitting in a system that is simultaneously processing normally, clearing a decade-long backlog, and preparing for migration. Clean, predictable approval timelines do not exist in this environment.

The regulatory direction is right. CRO registration will raise quality standards. DDRS will improve the infrastructure. But implementation has been painful, communication has been insufficient, and the organizations paying the heaviest price are often the smallest and the best.

The industry needs to talk about this more honestly.

The Regulatory Bottleneck That Is Stalling India's Clinical Trial Industry India's clinical research sector is at an inflection point. On paper, the regulatory reforms of 2024 and 2026 represent the most progressive evolution of the country's clinical trial framework in a decade — mandatory CRO re...

22/07/2026

Is your clinical trial data telling the whole story?
Randomised controlled trials prove efficacy under controlled conditions. But what happens when your drug meets real patients — with comorbidities, polypharmacy, and diverse lifestyles?
That's where Real World Evidence comes in.
At Genelife Clinical Research, we help global pharma and biotech companies bridge the gap between clinical trial results and real-world outcomes — through patient registries, observational studies, disease burden mapping, and market research that captures how treatments actually perform in practice.
India offers a unique advantage for RWE generation — 1.4 billion people, extraordinary disease diversity, and 40–60% lower costs than the US or Europe.
We've covered everything you need to know in our latest article.

This article explains what RWE and market research services entail, why they matter, and how Genelife's approach delivers actionable evidence

14/07/2026

The world's most commercially exciting nutraceutical ingredients come from India.
Ashwagandha. Curcumin. Boswellia. Brahmi. Moringa.
So does the deepest expertise in their phytochemistry, their supply chains, and their traditional use.
Yet most of the clinical trials for these ingredients have been run in the West.
That's a missed opportunity — scientifically, commercially, and strategically.
Monday's article makes the case for why India is the right place to generate clinical evidence for botanical nutraceuticals. Not just the most cost-efficient place. The right place.

Discover how India is becoming preferred destination for nutraceutical clinical research, botanical clinical trials, and real-world evidence studies.

12/07/2026

On Monday we published an article on the constraints in medical device clinical trials.
The one that gets underestimated most consistently:
Operator dependency.
In a pharmaceutical trial, you randomize patients. The drug is the same regardless of who prescribes it.
In a device trial, you also have to manage — implicitly — the randomization of operator skill. And you can't. A stent deployed by an experienced interventional cardiologist at a high-volume center produces different outcomes than the same stent deployed by a less experienced operator. A surgical robot's performance depends on technique, intraoperative decisions, and learning curve effects that vary systematically across operators.
The consequence: trial outcomes that reflect operator skill as much as device performance. Evidence that is not reproducible in the broader clinical community. Pivotal trial results that look different from post-market registry data — not because the device changed, but because the operator base did.
Managing this requires explicit design choices. Pre-defined operator qualification criteria. Structured proctoring. Centre-level outcome monitoring. Pre-specified analysis of outcomes by operator volume.
The trials that get this right produce evidence that is both more scientifically honest and more regulatory-credible.

Genelife Expertise in Medical Device Clinical Trials

07/07/2026

India isn't one epidemiological environment. It's at least three.

A still-substantial infectious disease burden — dengue, TB, vector-borne disease — that requires classical surveillance methodology. A rapidly accelerating non-communicable disease epidemic — diabetes, cardiovascular disease, CKD — that looks meaningfully different than it did five years ago. And a population scale and genetic diversity that makes safety signal detection and subgroup analysis possible in ways smaller markets simply can't support.

Most sponsors come to India for one of these reasons. The ones getting the most value are increasingly using the same surveillance and data infrastructure to answer questions across all three.

06/07/2026

Medical device clinical trials face constraints pharmaceutical trials don't:
→ No placebo control — you can't give someone a sham stent → No reversibility — an implanted device cannot be discontinued → No operator standardization — skill level varies and cannot be randomized → No stable product — the device iterates faster than the trial can report → No simple endpoint — device performance ≠ patient outcomes
Each of these is a structural feature of device research, not a problem that better methodology will eliminate.
The clinical programs that succeed are the ones designed by people who understand this — and build their strategy around it from day one.

Genelife Expertise in Medical Device Clinical Trials

02/07/2026

There's a paradox at the center of the global botanical nutraceutical market.

The ingredients generating the most commercial interest internationally — ashwagandha, curcumin, boswellia, brahmi, moringa — have their deepest roots in India. The traditional knowledge, the raw material supply chains, the phytochemical expertise, and the processing infrastructure are concentrated in India to a degree no other country approaches.

Yet most of the clinical evidence for these ingredients has been generated in Western research settings — often with Indian-sourced material, studied in Western populations, under Western regulatory frameworks.

That's changing. And this article makes the case for why India is actually the right place to generate clinical evidence for these ingredients — not just the cheapest place.

The ingredient expertise is here. The raw material supply chains are here. The patient populations most relevant to adaptogen, metabolic, and inflammatory research are here. And an internationally credible clinical research infrastructure that generates data acceptable to FDA, EMA, and TGA is here too.

For international nutraceutical companies building clinical programs around botanical ingredients, India isn't just a cost play. It's the location where everything aligns.

Discover how India is becoming preferred destination for nutraceutical clinical research, botanical clinical trials, and real-world evidence studies.

24/06/2026

India's healthcare landscape presents a unique opportunity for epidemiology research.
With a population of more than 1.4 billion people, remarkable genetic and environmental diversity, and a disease burden that spans both infectious diseases and rapidly growing chronic conditions, India has become one of the world's most valuable environments for disease surveillance, post-marketing safety monitoring, and real-world evidence generation.
For pharmaceutical companies, vaccine developers, biotech organizations, and public health agencies, understanding disease patterns, treatment outcomes, and population-level safety signals is becoming increasingly important for regulatory decision-making, market access, and healthcare planning.
In our latest article, we explore why India is emerging as a strategic destination for:
✔ Disease Surveillance Studies
✔ Epidemiology Research
✔ Post-Marketing Safety Surveillance
✔ Vaccine Safety Monitoring
✔ Disease Burden Studies
✔ Real-World Evidence (RWE) Generation
The article also discusses the regulatory, operational, and scientific considerations that international sponsors should understand when planning epidemiological research programs in India.

Explore how disease surveillance, epidemiology & real-world evidence studies in India help healthcare companies generate globally relevant data.

20/06/2026

We wrote about medical device clinical trial design in 2011.

The problem we identified then: no perfect control, operator dependency, trial outcomes that don't match real-world practice.

Fifteen years later — same problems. Dramatically better toolkit.

→ Adaptive designs: modify the trial as evidence accumulates
→ Bayesian frameworks: formally incorporate prior data
→ Platform trials: evaluate multiple device iterations simultaneously

→ Real-world evidence: extend the evidence base post-approval
→ EU MDR: made all of the above a regulatory requirement, not a choice

The era of minimal pre-market device evaluation is over.

Is your clinical program designed for the regulatory environment that exists today?

https://genelifecr.blogspot.com/2026/06/clinical-research-in-medical-devices.html

Explore advances in medical device clinical trials, including adaptive designs, RWE, EU MDR, and digital innovation.